Drug intelligence / Profile preview

G-0069A

Development stage: Discontinued
Lead developer: NAEJA-RGM Pharmaceuticals

Overview

G-0069A is a discontinued drug candidate that was under development by Naeja-RGM Pharmaceutical (formerly Naeja Pharmaceutical) for the treatment of neoplasms. Naeja-RGM was a Canadian contract research organization (CRO) based in Edmonton, Alberta, which specialized in the discovery and development of small molecule therapeutics, particularly in the areas of infectious diseases and oncology. Specific details regarding the chemical structure, molecular target, or mechanism of action of G-0069A have not been publicly disclosed in pharmaceutical databases or literature, and the program is currently listed as discontinued.

Beyond the preview

Go deeper on G-0069A.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on G-0069A.

Explore the full profile